rais est given upsid encourag pipelin
prospect increas pt old
new maintain ew wake
move share sinc march note potenti
posit newsflow drive share higher
rais revenu est ep rais revenue
boost ep
higher project carri year rais ep
pleas see report strong drive upsid guidanc
detail lilli second quarter upsid management updat
new drug trial develop watch year-end lilli
announc move gip/glp combo diabet ph winter
ph data present easd fall galcanezumab cgrp migrain
prevent approv oct estimate watch price vs competitor
trulic rewind cardiovascular outcom top-lin issu
assum success ulra rapid insulin initi ph top line releas like
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
base case ep premium peer
median due lilli better growth prospect
bull case ep
bull case ep
new product drive revenu upsid oper leverag boost ep
forecast price-to-earnings multipl expand strong execut repres
potenti addit upsid beyond bull case
base case ep
base case ep
see solid growth prospect balanc premium valuat new product
launch meet slightli exceed expect pipelin progress continu
bear case ep
bear case ep
us revenu growth disappoint drive earn expect
trulic demonstr cv superior rewind trial pipelin
disappoint occur multipl contract due lower growth expect
enthusiasm new product momentum
balanc premium valuat
consensu expect lilli drive
signific oper margin expans
rel low base long-term
quarterli result financi guidanc
verzenio trulic jardianc taltz
pipelin news flow includ
extern busi develop
risk achiev price
upsid risk posit financi result
project new product revenu
forecast financi result upsid
product disappoint compel extern
downsid risk financi result fall
short expect face us
compet drug surpris upsid
exhibit new vs old consensu estim
price
price
valuat methodolog risk associ price target rate recommend referenc research report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres
morgan stanley research broadway attent research manag new york ny usa
price data
price data
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
